Log In
BCIQ
Print this Print this
 

REGN1908-1909

  Manage Alerts
Collapse Summary General Information
Company Regeneron Pharmaceuticals Inc.
Description mAb combination against an undisclosed target
Molecular Target Undisclosed
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I
Standard IndicationAllergy
Indication DetailsTreat allergy
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today